MedPath

Ayurvedic Treatment for Intra-ocular Hypertension (Glaucoma)

Phase 1/2
Recruiting
Conditions
Other specified disorders of eye and adnexa,
Registration Number
CTRI/2020/08/027255
Lead Sponsor
Dr Arun Das
Brief Summary

The study is a randomized controlled clinical study to evaluate the Efficacy of Ayurvedic protocol (Nasya, Pindi Bidalaka and Anjana) in intra ocular hydrops or ocular hypertension and to compare with Standard Anti glaucoma medication (Timolol Melatate 0.5%) for a period of 45 days. Study will be conducted in KAHERs Shri B M Kankanawadi Ayurveda Mahavidyalaya and Research centre owned KLE Ayurveda Hospital Shahapur BELAGAVI Karnataka India . The expected outcome is to bring down the raised IOP to  standard target IOP  and prevent the consequences resulting out of intraocular  hydrops

Detailed Description

Not available

Recruitment & Eligibility

Status
Open to Recruitment
Sex
All
Target Recruitment
20
Inclusion Criteria

IOP between 22 to 30 mm of Hg(Asymptomatic cases but noticed raised IOP during routine ophthalmic investigations) Age group 30 to 70years Irrespective of sex, occupation Controlled systemic ailments like DM & HTN Known cases of POAG with existing standard anti-glaucoma medication with Timilol Maleate 0.5%.

Exclusion Criteria

Acute Angle closure glaucoma IOP ranging above 30mm of Hg Un-controlled systemic disorders like DM, HTN, COPD, Renal pathologies End-stage / advanced glaucomatous optic neuropathywith sever visual morbidity.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
The developed Ayurvedic Protocol may be effective in maanaging IOP at its trget45 days
Secondary Outcome Measures
NameTimeMethod
The developed protocol may be effective in Preventing complications of ocular hydrops45 days

Trial Locations

Locations (1)

OPD No 27

🇮🇳

Belgaum, KARNATAKA, India

OPD No 27
🇮🇳Belgaum, KARNATAKA, India
Dr Arun Das
Principal investigator
9164537685
drarundasayu@gmail.com

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.